PT3651768T - Inibidores heterocíclicos da atr cinase - Google Patents
Inibidores heterocíclicos da atr cinaseInfo
- Publication number
- PT3651768T PT3651768T PT188311047T PT18831104T PT3651768T PT 3651768 T PT3651768 T PT 3651768T PT 188311047 T PT188311047 T PT 188311047T PT 18831104 T PT18831104 T PT 18831104T PT 3651768 T PT3651768 T PT 3651768T
- Authority
- PT
- Portugal
- Prior art keywords
- atr kinase
- heterocyclic inhibitors
- heterocyclic
- inhibitors
- atr
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762531951P | 2017-07-13 | 2017-07-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3651768T true PT3651768T (pt) | 2024-03-20 |
Family
ID=64998660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT188311047T PT3651768T (pt) | 2017-07-13 | 2018-07-13 | Inibidores heterocíclicos da atr cinase |
Country Status (15)
Country | Link |
---|---|
US (3) | US10392376B2 (pt) |
EP (1) | EP3651768B1 (pt) |
JP (1) | JP7159307B2 (pt) |
KR (1) | KR20200028441A (pt) |
CN (2) | CN111867590B (pt) |
AU (1) | AU2018301696B8 (pt) |
CA (1) | CA3069693A1 (pt) |
DK (1) | DK3651768T3 (pt) |
FI (1) | FI3651768T3 (pt) |
IL (1) | IL271930B (pt) |
LT (1) | LT3651768T (pt) |
MX (1) | MX2020000386A (pt) |
PH (1) | PH12020500072A1 (pt) |
PT (1) | PT3651768T (pt) |
WO (1) | WO2019014618A1 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
LT3651768T (lt) | 2017-07-13 | 2024-04-25 | Board Of Regents, The University Of Texas System | Heterocikliniai atr kinazės inhibitoriai |
US10800774B2 (en) | 2017-08-17 | 2020-10-13 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
CN111655688B (zh) * | 2017-09-08 | 2023-09-29 | 蓝谷制药有限责任公司 | 经取代的吡咯并吡啶类化合物作为atr抑制剂 |
CN112218631B (zh) * | 2018-03-16 | 2023-12-22 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
US20220041588A1 (en) * | 2018-09-27 | 2022-02-10 | Fochon Pharmaceuticals, Ltd. | Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors |
US20220378799A1 (en) * | 2019-06-06 | 2022-12-01 | Beijing Tide Pharmaceutical Co., Ltd. | 2, 4, 6-tri-substituted pyrimidine compound as atr kinase inhibitor |
AU2021282122B2 (en) * | 2020-05-29 | 2023-09-21 | Wuxi Life Fountain Biotech Co., Ltd | Fluoropyrrolopyridine compound and application thereof |
CN116848113A (zh) * | 2021-02-10 | 2023-10-03 | 南京再明医药有限公司 | 作为hpk1抑制剂的双环类化合物及其应用 |
WO2022262143A1 (zh) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | 一种吡啶硼酸酯的制备方法 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001081338A1 (en) * | 2000-04-25 | 2001-11-01 | Actelion Pharmaceuticals Ltd | Substituted sulfonylaminopyrimidines |
JP2009523161A (ja) * | 2006-01-11 | 2009-06-18 | アストラゼネカ アクチボラグ | モルホリノピリミジン誘導体と療法におけるその使用 |
CA2660758A1 (en) | 2006-08-24 | 2008-02-27 | Astrazeneca Ab | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
EP2064203A1 (en) | 2006-09-14 | 2009-06-03 | AstraZeneca AB | 2-benzimidaz0lyl-6-m0rph0lin0-4-piperidin-4-ylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2008125833A1 (en) | 2007-04-12 | 2008-10-23 | Piramed Limited | Pharmaceutical compounds |
US20080292588A1 (en) | 2007-05-17 | 2008-11-27 | Anadys Pharmaceuticals, Inc. | 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives |
AU2008273889B2 (en) | 2007-07-09 | 2012-03-08 | Astrazeneca Ab | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
EP2176256A2 (en) | 2007-07-09 | 2010-04-21 | AstraZeneca AB | Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases |
ATE554075T1 (de) | 2007-07-09 | 2012-05-15 | Astrazeneca Ab | Bei mit mtor-kinase und/oder pi3k in zusammenhang stehenden krankheiten angewendete morpholinopyrimidinderivate |
AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
CA2728559A1 (en) | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
UY32351A (es) | 2008-12-22 | 2010-07-30 | Astrazeneca Ab | Compuestos de pirimidinil indol para uso como inhibidores de atr |
WO2010120996A1 (en) | 2009-04-17 | 2010-10-21 | Wyeth Llc | 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
JP2013032290A (ja) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | 新規縮合ピリミジン誘導体 |
WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
WO2011106276A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
EP2542536B1 (en) | 2010-03-04 | 2015-01-21 | Cellzome Limited | Morpholino substituted urea derivatives as mtor inhibitors |
WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
SA111320519B1 (ar) | 2010-06-11 | 2014-07-02 | Astrazeneca Ab | مركبات بيريميدينيل للاستخدام كمثبطات atr |
UA112517C2 (uk) | 2010-07-06 | 2016-09-26 | Новартіс Аг | Тетрагідропіридопіримідинові похідні |
WO2012147890A1 (ja) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
DK3486245T3 (da) | 2012-12-07 | 2021-07-19 | Vertex Pharma | 2-amino-n-(piperidin-1-yl-pyridin-3-yl) pyrazolo[1,5alpha]pyrimidin-3-carboxamid som hæmmer for atr kinase |
ES2893725T3 (es) | 2013-04-19 | 2022-02-09 | Incyte Holdings Corp | Heterocíclicos bicíclicos como inhibidores del FGFR |
SI3077397T1 (sl) | 2013-12-06 | 2020-02-28 | Vertex Pharmaceuticals Inc. | 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)pirazolo(1,5-A)pirimidin-3- karboksamidna spojina, koristna kot inhibitor kinaze ATR, njena priprava, različne trdne oblike in njeni radioaktivno označeni derivati |
US9695171B2 (en) | 2013-12-17 | 2017-07-04 | Pfizer Inc. | 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors |
SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | 2-(嗎啉-4-基)-1,7-萘啶 |
US9663535B2 (en) | 2014-10-13 | 2017-05-30 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors |
CA3026149A1 (en) | 2016-06-02 | 2017-12-07 | Cadent Therapeutics, Inc. | Potassium channel modulators |
WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
LT3651768T (lt) * | 2017-07-13 | 2024-04-25 | Board Of Regents, The University Of Texas System | Heterocikliniai atr kinazės inhibitoriai |
US10800774B2 (en) | 2017-08-17 | 2020-10-13 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of ATR kinase |
CN112218631B (zh) | 2018-03-16 | 2023-12-22 | 德州大学系统董事会 | Atr激酶的杂环抑制剂 |
-
2018
- 2018-07-13 LT LTEPPCT/US2018/042128T patent/LT3651768T/lt unknown
- 2018-07-13 FI FIEP18831104.7T patent/FI3651768T3/fi active
- 2018-07-13 KR KR1020207004080A patent/KR20200028441A/ko not_active Application Discontinuation
- 2018-07-13 US US16/035,310 patent/US10392376B2/en active Active
- 2018-07-13 CN CN201880051484.9A patent/CN111867590B/zh active Active
- 2018-07-13 MX MX2020000386A patent/MX2020000386A/es unknown
- 2018-07-13 AU AU2018301696A patent/AU2018301696B8/en active Active
- 2018-07-13 CA CA3069693A patent/CA3069693A1/en active Pending
- 2018-07-13 PT PT188311047T patent/PT3651768T/pt unknown
- 2018-07-13 CN CN202311427557.9A patent/CN117466884A/zh active Pending
- 2018-07-13 WO PCT/US2018/042128 patent/WO2019014618A1/en active Application Filing
- 2018-07-13 JP JP2020523235A patent/JP7159307B2/ja active Active
- 2018-07-13 IL IL271930A patent/IL271930B/en unknown
- 2018-07-13 EP EP18831104.7A patent/EP3651768B1/en active Active
- 2018-07-13 DK DK18831104.7T patent/DK3651768T3/da active
-
2019
- 2019-07-10 US US16/507,851 patent/US10800769B2/en active Active
-
2020
- 2020-01-09 PH PH12020500072A patent/PH12020500072A1/en unknown
- 2020-09-01 US US17/009,428 patent/US11434233B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3651768B1 (en) | 2023-12-20 |
AU2018301696B8 (en) | 2023-03-23 |
US11434233B2 (en) | 2022-09-06 |
JP2020527174A (ja) | 2020-09-03 |
AU2018301696A8 (en) | 2023-03-23 |
CA3069693A1 (en) | 2019-01-17 |
WO2019014618A1 (en) | 2019-01-17 |
MX2020000386A (es) | 2020-08-06 |
PH12020500072A1 (en) | 2020-11-09 |
EP3651768A1 (en) | 2020-05-20 |
US20190016713A1 (en) | 2019-01-17 |
AU2018301696B2 (en) | 2022-10-27 |
AU2018301696A1 (en) | 2020-02-27 |
LT3651768T (lt) | 2024-04-25 |
CN111867590A (zh) | 2020-10-30 |
US10392376B2 (en) | 2019-08-27 |
CN111867590B (zh) | 2023-11-17 |
KR20200028441A (ko) | 2020-03-16 |
US10800769B2 (en) | 2020-10-13 |
EP3651768A4 (en) | 2021-04-07 |
US20210047311A1 (en) | 2021-02-18 |
DK3651768T3 (da) | 2024-03-18 |
FI3651768T3 (fi) | 2024-03-14 |
JP7159307B2 (ja) | 2022-10-24 |
IL271930A (en) | 2020-02-27 |
US20200102296A1 (en) | 2020-04-02 |
IL271930B (en) | 2022-07-01 |
CN117466884A (zh) | 2024-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL271930A (en) | Heterocyclic inhibitors of ATR kinase | |
HK1246645A1 (zh) | 細胞周期蛋白依賴性激酶的抑制劑 | |
HK1245244A1 (zh) | 作爲激酶抑制劑的雜環酰胺 | |
EP3668839A4 (en) | HETEROCYCLIC INHIBITORS OF THE ATR KINASE | |
EP3177295A4 (en) | Uses of salt-inducible kinase (sik) inhibitors | |
IL268614A (en) | Aminotriazolopyridines as kinase inhibitors | |
IL271109A (en) | Imidazole-containing alk2 kinase inhibitors | |
IL279949A (en) | Heterocyclic MCT4 inhibitors | |
IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
EP3405477C0 (en) | INHIBITORS OF TRANSGLUTAMINASE | |
EP3765008A4 (en) | HETEROCYCLIC INHIBITORS OF THE ATR KINASE | |
IL266789A (en) | Heterocyclic compounds as kinase inhibitors | |
IL274207A (en) | Aminoimidazopyridazines as kinase inhibitors | |
IL282588A (en) | Heterocyclic kinase inhibitors and their use | |
GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
GB201708451D0 (en) | Inhibitors of metallo-beta-lactamases | |
EP3347357A4 (en) | HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY |